Opinion|Videos|January 1, 2025

Role of Lp(a) in ASCVD Risk

Key Takeaways

  • Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
  • Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
SHOW MORE

Panelists discuss how Lp(a), a distinct lipoprotein particle from LDL, independently contributes to ASCVD risk through its unique structural properties and atherogenic potential.

Video content above is prompted by the following:

  • What is the role played by lipoprotein(a) (Lp[a]) in developing ASCVD?
    • How does Lp(a) differ from LDL?

Related to this article

HCPLive Five at CHEST 2026
Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.